Tessa Therapeutics Closes USD 80 Million Financing Round Led by Temasek
Proceeds to be used to further develop Tessa’s advanced solid tumor immunotherapy pipeline. Funding round…
Continue Reading
-
-
Tessa Therapeutics Appoints Mr. Desmond Lim as Chief Financial Officer
Tessa Therapeutics, a clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for solid tumors,…
Continue Reading -
Tessa Therapeutics Appoints Ms. Jennifer Butler as Chief Commercial Officer
Tessa Therapeutics (Tessa), a clinical stage biopharmaceutical company, today announced the appointment of Ms. Jennifer…
Continue Reading -
Tessa Therapeutics and Parker Institute for Cancer Immunotherapy Enter into Strategic Alliance Agreement
Tessa Therapeutics (Tessa) and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced the…
Continue Reading -
Tessa Therapeutics Identifies Predictive Biomarkers for Efficacy of Cancer Immunotherapies and Patient Survival
Tessa Therapeutics (Tessa) presented biomarker data from its Phase II trial for its lead candidate…
Continue Reading -
Tessa Therapeutics and Vyriad Form Partnership to Create Next Generation of Cancer Immunotherapy Treatments
Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, and Vyriad, an…
Continue Reading -
Tessa Therapeutics Announces Acquisition of Euchloe Bio
Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, today announced the…
Continue Reading -
Tessa Therapeutics announce creation of an Immuno-Oncology Laboratory with A*STAR’s Institute of Molecular and Cell Biology
Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, today announced the…
Continue Reading